Is Biotech's Health Improving?

S&P's fundamental outlook for the industry is neutral. But it has buy recommendations on some with novel therapies and strong patents

The S&P 1500 Biotechnology subindustry index recently saw its relative strength ranking move up one notch, from 3 to 4, indicating that its trailing 12-month price performance is now in the top 30% of all subindustry indexes in the S&P 1500 (a ranking of 5 would place it in the top 10%). Year to date through Mar. 28, the S&P Biotechnology index rose 0.8%, vs. a 10.3% decline for the S&P 1500.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.